International Biotechnology Trust PLC purchased a new position in Immunic during the second quarter worth approximately $1,531,000. This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein.
Shares of IMUX can be purchased through any online brokerage account. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations.
The top two institutional holders are Omega Fund Management (US) Inc. with over 1.37 Million shares worth more than $16.62 Million. Let's conquer your financial goals together...faster. Stocks: Real-time U.S. stock quotes reflect trades reported through Nasdaq only; comprehensive quotes and volume reflect trading in all markets and are delayed at least 15 minutes. The expected earnings per share for the stock is -$0.62. Zacks Equity Research Source: FactSet, Indexes: Index quotes may be real-time or delayed as per exchange requirements; refer to time stamps for information on any delays. Company profile page for Immunic Inc including stock price, company news, press releases, executives, board members, and contact information
Immunic has received 59 “outperform” votes. However, we can attribute Immunic's gains on the stock market today to a nod of approval from a Wall Street analyst. Finally, Hudson Bay Capital Management LP purchased a new position in shares of Immunic in the second quarter valued at approximately $1,491,000. Several institutional investors and hedge funds have recently modified their holdings of IMUX. Click here to see O'Reilly's controversial new me$$age (before it's gone!). Export data to Excel for your own analysis. The projected low price target is $45 while the price target rests at a high of $71. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. How is the ViewRay, Inc. (NASDAQ:VRAY) performance outlook for the coming months? View analysts' price targets for Immunic. Also the top two Mutual Funds that are holding company’s shares are Vanguard Total Stock Market Index Fund and iShares Russell 2000 ETF.
Source: FactSet, Markets Diary: Data on U.S. Overview page represent trading in all U.S. markets and updates until 8 p.m. See Closing Diaries table for 4 p.m. closing data. To see all exchange delays and terms of use please see disclaimer. All rights reserved.
Sporting 0.21% in the green today, the stock has traded in the green over the last five days, with the highest price hit on Friday, Oct 02 when the IMUX stock price touched $20.58- or saw a rise of 8.11%. Piper Sandler assumed coverage on Immunic in a report on Tuesday, August 25th. This includes personalizing content and advertising. After all, the clinical trial process is rife with risk and uncertainty, and if one of the company's candidates fails to deliver positive results, its stock will plunge. Learn more.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply. Visit www.zacksdata.com to get our data and content for your mobile app or website. Immunic's stock was trading at $7.75 on March 11th, 2020 when COVID-19 reached pandemic status according to the World Health Organization (WHO). Immunic, Inc. is headquartered in New York, New York. But this new O'Reilly message is a lot different…It's about a single strategy that's being called "the smartest investment strategy of all-time." (Add your “underperform” vote.). In fact, over the past month, current quarter estimates have narrowed from a loss of 80 cents per share to a loss of 75 cents per share, while current year estimates have narrowed from a loss of $2.93 per share to a loss of $2.89 per share. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. All rights reserved. The disclosure for this sale can be found here. Delayed quotes by Sungard.
News Corp is a network of leading companies in the worlds of diversified media, news, education, and information services. Get short term trading ideas from the MarketBeat Idea Engine. Vote “Underperform” if you believe IMUX will underperform the S&P 500 over the long term. Leap Investments LP purchased a new position in Immunic during the second quarter worth approximately $139,000. Sasol Limited (SSL) investors to reap big returns again.
Zero analysts have provided estimates for Immunic’s earnings, with the highest EPS estimate coming in at ($0.55) and the lowest estimate coming in at ($0.74). Sources: FactSet, Tullett Prebon, Currencies: Currency quotes are updated in real-time. One stock that might be an intriguing choice for investors right now is Immunic, Inc. (IMUX - Free Report). If we evaluate the company’s growth over the last 5-year and for the next 5-year period, we find that annual earnings growth was +49.8% over the past 5 years. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. The firm has a market cap of $289.33 million, a PE ratio of -6.30 and a beta of 2.70. Immunic, Inc., a clinical-stage biopharmaceutical company, develops a pipeline of selective oral immunology therapies for the treatment of chronic inflammatory and autoimmune diseases, including relapsing-remitting multiple sclerosis, ulcerative colitis, Crohn's disease, and psoriasis. Sources: FactSet, Dow Jones, ETF Movers: Includes ETFs & ETNs with volume of at least 50,000. Investors are also buoyed by the number of investors in a company, with Immunic, Inc. having a total of 36 institutions that hold shares in the company.
One stock that might be an intriguing choice for investors right now is Immunic, Inc. IMUX. Zero analysts have provided estimates for Immunic’s earnings, with the highest EPS estimate coming in at ($0.55) and the lowest estimate coming in at ($0.74). Immunic, Inc. IMUX 20.37 0.82 (4.19%). Company profile page for Immunic AG including stock price, company news, press releases, executives, board members, and contact information
NASDAQ:IMUX opened at $19.33 on Friday. Its lead development program is IMU-838, a selective immune modulator that inhibits the intracellular metabolism of activated immune cells by blocking the enzyme DHODH, which is in phase II clinical development for treatment of ulcerative colitis and relapsing-remitting multiple sclerosis. Considering the fact that Immunic's shares closed at $14.42 apiece during the previous trading session -- and are still worth about $16.79 as of this writing -- Rahimi's price target represents a significant upside for the healthcare company. An in-depth look at the Medtronic plc (MDT) stock. Based on an average trading volume of 637,000 shares, the short-interest ratio is currently 1.7 days. Wells Fargo & Company MN now owns 10,814 shares of the company’s stock worth $65,000 after buying an additional 4,769 shares during the last quarter. The company is expected to report its next earnings results on Thursday, November 5th. Is It Finally Time to Buy Marijuana Stocks. Immunic (NASDAQ:IMUX) last issued its earnings results on Sunday, August 2nd. Equities analysts expect Immunic (NASDAQ:IMUX) to report earnings of ($0.61) per share for the current fiscal quarter, according to Zacks Investment Research. Source: FactSet. Immunic does not have a long track record of dividend growth. The shares were sold at an average price of $14.68, for a total value of $92,484.00. Learn everything you need to know about successful options trading with this three-part video course.
Gilead Sciences, Inc. (GILD): What is good about stock? One of the company's leading pipeline candidates is IMU-838, a potential medicine for relapsing-remitting multiple sclerosis (RRMS). Shares of The Charles Schwab Corporation (NYSE:SCHW) gained 4.16% in a month. Immunic has a fifty-two week low of $4.19 and a fifty-two week high of $23.39. The consensus among analysts is that Immunic, Inc. (IMUX) is a Buy stock at the moment, with a recommendation rating of 1.5. Finally, ValuEngine downgraded Immunic from a “strong-buy” rating to a “buy” rating in a report on Tuesday, September 15th. Their forecasts range from $45.00 to $71.00. Immunic's management team includes the following people: Everyone knows California is nuts. Shares of Immunic, Inc. (NASDAQ:IMUX) gained 24.74% in a month.
Learn more. View which stocks have been most impacted by COVID-19. FactSet (a) does not make any express or implied warranties of any kind regarding the data, including, without limitation, any warranty of merchantability or fitness for a particular purpose or use; and (b) shall not be liable for any errors, incompleteness, interruption or delay, action taken in reliance on any data, or for any damages resulting therefrom. Immunic has a market capitalization of $283.04 million. Source: Kantar Media. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: You have already added five stocks to your watchlist. Immunic has been the subject of 7 research reports in the past 90 days, demonstrating strong analyst interest in this stock. The company can be reached via phone at 332-255-9818 or via email at [email protected]. Data are provided 'as is' for informational purposes only and are not intended for trading purposes. A number of analysts recently commented on IMUX shares. Earnings growth for 2020 is a modest +88.4% while over the next 5 years, the company’s earnings are expected to increase by 15.5%. To learn more, click here. NYSE and AMEX data is at least 20 minutes delayed. Philip Morris International Inc. (PM) has great growth outlook for 2020, Shares in Grubhub Inc. (GRUB) 66.08 % up, YTD, Baidu, Inc. (BIDU) investors to reap big returns again. These returns cover a period from January 1, 1988 through August 31, 2020. The Ascent is The Motley Fool's new personal finance brand devoted to helping you live a richer life. Here’s a small-cap explorer that’s deploying a proven strategy that’s so lucrative, it recently sold an interest in one of its properties to a global producer for over C$25 million in cash and stock. View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. IA "Marketing Sentinel" seeks to provide the news and analytical information to both American and foreign audiences, events and events in the USA and all over the world reliably, objectively and promptly. The company's average rating score is 3.00, and is based on 7 buy ratings, no hold ratings, and no sell ratings. They set an “overweight” rating and a $71.00 price target for the company. The IMUX stock price is -23.69% off its 52-week high price of $23.39 and 77.84% above the 52-week low of $4.19.
International Biotechnology Trust PLC purchased a new position in Immunic during the second quarter worth approximately $1,531,000. This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein.
Shares of IMUX can be purchased through any online brokerage account. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations.
The top two institutional holders are Omega Fund Management (US) Inc. with over 1.37 Million shares worth more than $16.62 Million. Let's conquer your financial goals together...faster. Stocks: Real-time U.S. stock quotes reflect trades reported through Nasdaq only; comprehensive quotes and volume reflect trading in all markets and are delayed at least 15 minutes. The expected earnings per share for the stock is -$0.62. Zacks Equity Research Source: FactSet, Indexes: Index quotes may be real-time or delayed as per exchange requirements; refer to time stamps for information on any delays. Company profile page for Immunic Inc including stock price, company news, press releases, executives, board members, and contact information
Immunic has received 59 “outperform” votes. However, we can attribute Immunic's gains on the stock market today to a nod of approval from a Wall Street analyst. Finally, Hudson Bay Capital Management LP purchased a new position in shares of Immunic in the second quarter valued at approximately $1,491,000. Several institutional investors and hedge funds have recently modified their holdings of IMUX. Click here to see O'Reilly's controversial new me$$age (before it's gone!). Export data to Excel for your own analysis. The projected low price target is $45 while the price target rests at a high of $71. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. How is the ViewRay, Inc. (NASDAQ:VRAY) performance outlook for the coming months? View analysts' price targets for Immunic. Also the top two Mutual Funds that are holding company’s shares are Vanguard Total Stock Market Index Fund and iShares Russell 2000 ETF.
Source: FactSet, Markets Diary: Data on U.S. Overview page represent trading in all U.S. markets and updates until 8 p.m. See Closing Diaries table for 4 p.m. closing data. To see all exchange delays and terms of use please see disclaimer. All rights reserved.
Sporting 0.21% in the green today, the stock has traded in the green over the last five days, with the highest price hit on Friday, Oct 02 when the IMUX stock price touched $20.58- or saw a rise of 8.11%. Piper Sandler assumed coverage on Immunic in a report on Tuesday, August 25th. This includes personalizing content and advertising. After all, the clinical trial process is rife with risk and uncertainty, and if one of the company's candidates fails to deliver positive results, its stock will plunge. Learn more.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply. Visit www.zacksdata.com to get our data and content for your mobile app or website. Immunic's stock was trading at $7.75 on March 11th, 2020 when COVID-19 reached pandemic status according to the World Health Organization (WHO). Immunic, Inc. is headquartered in New York, New York. But this new O'Reilly message is a lot different…It's about a single strategy that's being called "the smartest investment strategy of all-time." (Add your “underperform” vote.). In fact, over the past month, current quarter estimates have narrowed from a loss of 80 cents per share to a loss of 75 cents per share, while current year estimates have narrowed from a loss of $2.93 per share to a loss of $2.89 per share. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. All rights reserved. The disclosure for this sale can be found here. Delayed quotes by Sungard.
News Corp is a network of leading companies in the worlds of diversified media, news, education, and information services. Get short term trading ideas from the MarketBeat Idea Engine. Vote “Underperform” if you believe IMUX will underperform the S&P 500 over the long term. Leap Investments LP purchased a new position in Immunic during the second quarter worth approximately $139,000. Sasol Limited (SSL) investors to reap big returns again.
Zero analysts have provided estimates for Immunic’s earnings, with the highest EPS estimate coming in at ($0.55) and the lowest estimate coming in at ($0.74). Sources: FactSet, Tullett Prebon, Currencies: Currency quotes are updated in real-time. One stock that might be an intriguing choice for investors right now is Immunic, Inc. (IMUX - Free Report). If we evaluate the company’s growth over the last 5-year and for the next 5-year period, we find that annual earnings growth was +49.8% over the past 5 years. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. The firm has a market cap of $289.33 million, a PE ratio of -6.30 and a beta of 2.70. Immunic, Inc., a clinical-stage biopharmaceutical company, develops a pipeline of selective oral immunology therapies for the treatment of chronic inflammatory and autoimmune diseases, including relapsing-remitting multiple sclerosis, ulcerative colitis, Crohn's disease, and psoriasis. Sources: FactSet, Dow Jones, ETF Movers: Includes ETFs & ETNs with volume of at least 50,000. Investors are also buoyed by the number of investors in a company, with Immunic, Inc. having a total of 36 institutions that hold shares in the company.
One stock that might be an intriguing choice for investors right now is Immunic, Inc. IMUX. Zero analysts have provided estimates for Immunic’s earnings, with the highest EPS estimate coming in at ($0.55) and the lowest estimate coming in at ($0.74). Immunic, Inc. IMUX 20.37 0.82 (4.19%). Company profile page for Immunic AG including stock price, company news, press releases, executives, board members, and contact information
NASDAQ:IMUX opened at $19.33 on Friday. Its lead development program is IMU-838, a selective immune modulator that inhibits the intracellular metabolism of activated immune cells by blocking the enzyme DHODH, which is in phase II clinical development for treatment of ulcerative colitis and relapsing-remitting multiple sclerosis. Considering the fact that Immunic's shares closed at $14.42 apiece during the previous trading session -- and are still worth about $16.79 as of this writing -- Rahimi's price target represents a significant upside for the healthcare company. An in-depth look at the Medtronic plc (MDT) stock. Based on an average trading volume of 637,000 shares, the short-interest ratio is currently 1.7 days. Wells Fargo & Company MN now owns 10,814 shares of the company’s stock worth $65,000 after buying an additional 4,769 shares during the last quarter. The company is expected to report its next earnings results on Thursday, November 5th. Is It Finally Time to Buy Marijuana Stocks. Immunic (NASDAQ:IMUX) last issued its earnings results on Sunday, August 2nd. Equities analysts expect Immunic (NASDAQ:IMUX) to report earnings of ($0.61) per share for the current fiscal quarter, according to Zacks Investment Research. Source: FactSet. Immunic does not have a long track record of dividend growth. The shares were sold at an average price of $14.68, for a total value of $92,484.00. Learn everything you need to know about successful options trading with this three-part video course.
Gilead Sciences, Inc. (GILD): What is good about stock? One of the company's leading pipeline candidates is IMU-838, a potential medicine for relapsing-remitting multiple sclerosis (RRMS). Shares of The Charles Schwab Corporation (NYSE:SCHW) gained 4.16% in a month. Immunic has a fifty-two week low of $4.19 and a fifty-two week high of $23.39. The consensus among analysts is that Immunic, Inc. (IMUX) is a Buy stock at the moment, with a recommendation rating of 1.5. Finally, ValuEngine downgraded Immunic from a “strong-buy” rating to a “buy” rating in a report on Tuesday, September 15th. Their forecasts range from $45.00 to $71.00. Immunic's management team includes the following people: Everyone knows California is nuts. Shares of Immunic, Inc. (NASDAQ:IMUX) gained 24.74% in a month.
Learn more. View which stocks have been most impacted by COVID-19. FactSet (a) does not make any express or implied warranties of any kind regarding the data, including, without limitation, any warranty of merchantability or fitness for a particular purpose or use; and (b) shall not be liable for any errors, incompleteness, interruption or delay, action taken in reliance on any data, or for any damages resulting therefrom. Immunic has a market capitalization of $283.04 million. Source: Kantar Media. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: You have already added five stocks to your watchlist. Immunic has been the subject of 7 research reports in the past 90 days, demonstrating strong analyst interest in this stock. The company can be reached via phone at 332-255-9818 or via email at [email protected]. Data are provided 'as is' for informational purposes only and are not intended for trading purposes. A number of analysts recently commented on IMUX shares. Earnings growth for 2020 is a modest +88.4% while over the next 5 years, the company’s earnings are expected to increase by 15.5%. To learn more, click here. NYSE and AMEX data is at least 20 minutes delayed. Philip Morris International Inc. (PM) has great growth outlook for 2020, Shares in Grubhub Inc. (GRUB) 66.08 % up, YTD, Baidu, Inc. (BIDU) investors to reap big returns again. These returns cover a period from January 1, 1988 through August 31, 2020. The Ascent is The Motley Fool's new personal finance brand devoted to helping you live a richer life. Here’s a small-cap explorer that’s deploying a proven strategy that’s so lucrative, it recently sold an interest in one of its properties to a global producer for over C$25 million in cash and stock. View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. IA "Marketing Sentinel" seeks to provide the news and analytical information to both American and foreign audiences, events and events in the USA and all over the world reliably, objectively and promptly. The company's average rating score is 3.00, and is based on 7 buy ratings, no hold ratings, and no sell ratings. They set an “overweight” rating and a $71.00 price target for the company. The IMUX stock price is -23.69% off its 52-week high price of $23.39 and 77.84% above the 52-week low of $4.19.
IMUX updated stock price target summary. Most of the stocks in this report are flying under Wall Street radar, which provides a great opportunity to get in on the ground floor. The firm has seen solid earnings estimate revision activity over the past month, suggesting analysts are becoming a bit more bullish on the firm’s prospects in both the short and long term.
We use cookies to understand how you use our site and to improve your experience.
Fisker Inc (NYSE:SPAQ) Stock: The Next Big Player in EV? Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. There are currently 7 buy ratings for the stock, resulting in a consensus recommendation of "Buy."
International Biotechnology Trust PLC purchased a new position in Immunic during the second quarter worth approximately $1,531,000. This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein.
Shares of IMUX can be purchased through any online brokerage account. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations.
The top two institutional holders are Omega Fund Management (US) Inc. with over 1.37 Million shares worth more than $16.62 Million. Let's conquer your financial goals together...faster. Stocks: Real-time U.S. stock quotes reflect trades reported through Nasdaq only; comprehensive quotes and volume reflect trading in all markets and are delayed at least 15 minutes. The expected earnings per share for the stock is -$0.62. Zacks Equity Research Source: FactSet, Indexes: Index quotes may be real-time or delayed as per exchange requirements; refer to time stamps for information on any delays. Company profile page for Immunic Inc including stock price, company news, press releases, executives, board members, and contact information
Immunic has received 59 “outperform” votes. However, we can attribute Immunic's gains on the stock market today to a nod of approval from a Wall Street analyst. Finally, Hudson Bay Capital Management LP purchased a new position in shares of Immunic in the second quarter valued at approximately $1,491,000. Several institutional investors and hedge funds have recently modified their holdings of IMUX. Click here to see O'Reilly's controversial new me$$age (before it's gone!). Export data to Excel for your own analysis. The projected low price target is $45 while the price target rests at a high of $71. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. How is the ViewRay, Inc. (NASDAQ:VRAY) performance outlook for the coming months? View analysts' price targets for Immunic. Also the top two Mutual Funds that are holding company’s shares are Vanguard Total Stock Market Index Fund and iShares Russell 2000 ETF.
Source: FactSet, Markets Diary: Data on U.S. Overview page represent trading in all U.S. markets and updates until 8 p.m. See Closing Diaries table for 4 p.m. closing data. To see all exchange delays and terms of use please see disclaimer. All rights reserved.
Sporting 0.21% in the green today, the stock has traded in the green over the last five days, with the highest price hit on Friday, Oct 02 when the IMUX stock price touched $20.58- or saw a rise of 8.11%. Piper Sandler assumed coverage on Immunic in a report on Tuesday, August 25th. This includes personalizing content and advertising. After all, the clinical trial process is rife with risk and uncertainty, and if one of the company's candidates fails to deliver positive results, its stock will plunge. Learn more.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply. Visit www.zacksdata.com to get our data and content for your mobile app or website. Immunic's stock was trading at $7.75 on March 11th, 2020 when COVID-19 reached pandemic status according to the World Health Organization (WHO). Immunic, Inc. is headquartered in New York, New York. But this new O'Reilly message is a lot different…It's about a single strategy that's being called "the smartest investment strategy of all-time." (Add your “underperform” vote.). In fact, over the past month, current quarter estimates have narrowed from a loss of 80 cents per share to a loss of 75 cents per share, while current year estimates have narrowed from a loss of $2.93 per share to a loss of $2.89 per share. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. All rights reserved. The disclosure for this sale can be found here. Delayed quotes by Sungard.
News Corp is a network of leading companies in the worlds of diversified media, news, education, and information services. Get short term trading ideas from the MarketBeat Idea Engine. Vote “Underperform” if you believe IMUX will underperform the S&P 500 over the long term. Leap Investments LP purchased a new position in Immunic during the second quarter worth approximately $139,000. Sasol Limited (SSL) investors to reap big returns again.
Zero analysts have provided estimates for Immunic’s earnings, with the highest EPS estimate coming in at ($0.55) and the lowest estimate coming in at ($0.74). Sources: FactSet, Tullett Prebon, Currencies: Currency quotes are updated in real-time. One stock that might be an intriguing choice for investors right now is Immunic, Inc. (IMUX - Free Report). If we evaluate the company’s growth over the last 5-year and for the next 5-year period, we find that annual earnings growth was +49.8% over the past 5 years. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. The firm has a market cap of $289.33 million, a PE ratio of -6.30 and a beta of 2.70. Immunic, Inc., a clinical-stage biopharmaceutical company, develops a pipeline of selective oral immunology therapies for the treatment of chronic inflammatory and autoimmune diseases, including relapsing-remitting multiple sclerosis, ulcerative colitis, Crohn's disease, and psoriasis. Sources: FactSet, Dow Jones, ETF Movers: Includes ETFs & ETNs with volume of at least 50,000. Investors are also buoyed by the number of investors in a company, with Immunic, Inc. having a total of 36 institutions that hold shares in the company.
One stock that might be an intriguing choice for investors right now is Immunic, Inc. IMUX. Zero analysts have provided estimates for Immunic’s earnings, with the highest EPS estimate coming in at ($0.55) and the lowest estimate coming in at ($0.74). Immunic, Inc. IMUX 20.37 0.82 (4.19%). Company profile page for Immunic AG including stock price, company news, press releases, executives, board members, and contact information
NASDAQ:IMUX opened at $19.33 on Friday. Its lead development program is IMU-838, a selective immune modulator that inhibits the intracellular metabolism of activated immune cells by blocking the enzyme DHODH, which is in phase II clinical development for treatment of ulcerative colitis and relapsing-remitting multiple sclerosis. Considering the fact that Immunic's shares closed at $14.42 apiece during the previous trading session -- and are still worth about $16.79 as of this writing -- Rahimi's price target represents a significant upside for the healthcare company. An in-depth look at the Medtronic plc (MDT) stock. Based on an average trading volume of 637,000 shares, the short-interest ratio is currently 1.7 days. Wells Fargo & Company MN now owns 10,814 shares of the company’s stock worth $65,000 after buying an additional 4,769 shares during the last quarter. The company is expected to report its next earnings results on Thursday, November 5th. Is It Finally Time to Buy Marijuana Stocks. Immunic (NASDAQ:IMUX) last issued its earnings results on Sunday, August 2nd. Equities analysts expect Immunic (NASDAQ:IMUX) to report earnings of ($0.61) per share for the current fiscal quarter, according to Zacks Investment Research. Source: FactSet. Immunic does not have a long track record of dividend growth. The shares were sold at an average price of $14.68, for a total value of $92,484.00. Learn everything you need to know about successful options trading with this three-part video course.
Gilead Sciences, Inc. (GILD): What is good about stock? One of the company's leading pipeline candidates is IMU-838, a potential medicine for relapsing-remitting multiple sclerosis (RRMS). Shares of The Charles Schwab Corporation (NYSE:SCHW) gained 4.16% in a month. Immunic has a fifty-two week low of $4.19 and a fifty-two week high of $23.39. The consensus among analysts is that Immunic, Inc. (IMUX) is a Buy stock at the moment, with a recommendation rating of 1.5. Finally, ValuEngine downgraded Immunic from a “strong-buy” rating to a “buy” rating in a report on Tuesday, September 15th. Their forecasts range from $45.00 to $71.00. Immunic's management team includes the following people: Everyone knows California is nuts. Shares of Immunic, Inc. (NASDAQ:IMUX) gained 24.74% in a month.
Learn more. View which stocks have been most impacted by COVID-19. FactSet (a) does not make any express or implied warranties of any kind regarding the data, including, without limitation, any warranty of merchantability or fitness for a particular purpose or use; and (b) shall not be liable for any errors, incompleteness, interruption or delay, action taken in reliance on any data, or for any damages resulting therefrom. Immunic has a market capitalization of $283.04 million. Source: Kantar Media. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: You have already added five stocks to your watchlist. Immunic has been the subject of 7 research reports in the past 90 days, demonstrating strong analyst interest in this stock. The company can be reached via phone at 332-255-9818 or via email at [email protected]. Data are provided 'as is' for informational purposes only and are not intended for trading purposes. A number of analysts recently commented on IMUX shares. Earnings growth for 2020 is a modest +88.4% while over the next 5 years, the company’s earnings are expected to increase by 15.5%. To learn more, click here. NYSE and AMEX data is at least 20 minutes delayed. Philip Morris International Inc. (PM) has great growth outlook for 2020, Shares in Grubhub Inc. (GRUB) 66.08 % up, YTD, Baidu, Inc. (BIDU) investors to reap big returns again. These returns cover a period from January 1, 1988 through August 31, 2020. The Ascent is The Motley Fool's new personal finance brand devoted to helping you live a richer life. Here’s a small-cap explorer that’s deploying a proven strategy that’s so lucrative, it recently sold an interest in one of its properties to a global producer for over C$25 million in cash and stock. View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. IA "Marketing Sentinel" seeks to provide the news and analytical information to both American and foreign audiences, events and events in the USA and all over the world reliably, objectively and promptly. The company's average rating score is 3.00, and is based on 7 buy ratings, no hold ratings, and no sell ratings. They set an “overweight” rating and a $71.00 price target for the company. The IMUX stock price is -23.69% off its 52-week high price of $23.39 and 77.84% above the 52-week low of $4.19.